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Abstract 
 
Background: Pain is one of the most common complaints in patients. Combination of 
paracetamol and codeine is an alternative analgesic combination in chronic pain 
management. They belong to a different group of analgesic and have a different 
mechanism of action. Combination of these drugs gives a better potential in pain 
management.  However, these drugs also have a potential side effect on the kidney. 
Objective: This study was conducted to identify the effect of administration of 
paracetamol and codeine combination toward creatinine serum level on male Wistar 
rats. 
Methods: An experimental study of post-test only control group design. The sample 
was 20 Wistar rats, randomized into four groups: control group, a group receiving 
paracetamol 32 mg/kg body weight, a group receiving codeine 1,9 mg/kg body weight, 
and a group receiving paracetamol 32 mg/kg body weight and codeine 1,9 mg 
combination, administered four times a day orally using gastric instillation for 28 days. 
At the 29th day, blood is collected from retro-orbital vessel to measure the serum 
creatinine levels. Statistical analysis was conducted using ANOVA Test. 
Results: Obtained from statistical analysis, there is no significant difference in serum 
creatinine levels in Wistar rats given all treatment group (p > 0,05). 
Conclusion: There is no significant difference in serum creatinine levels between the 
administration of paracetamol and codeine combination compared to the control group. 
 
 
1. Introduction 
Pain is defined as an unpleasant sensory and or 
emotional experience, which is associated with actual 
or potential tissue damage. This sensation delivered 
to the brain through sensory neuron fibre.1  
Until now, pain is one of the most common 
complaints presented by patients. Approximately 50 
million Americans had chronic pain. 2 In England, it 
is estimated that 8 million people suffer chronic pain 
and 13% of its population have chronic pain varying 
from moderate to severe pain for more than six 
months. 3 
Based on the duration, pain can be classified into 
acute pain and chronic pain. It can also be classified 
based on the degree of intensity into three groups, 
which mild pain, moderate pain and severe pain. 
Acute pain lasts about 1 – 7 days, while chronic pain 
can last until six months or more. 4 
Pain management can be done through 
pharmacology and non-pharmacology therapy. A 
non-opioid analgesic such as NSAID and 
paracetamol or acetaminophen can be used for mild 
pain. Moderate pain can be treated by non-opioid 
analgesic as monotherapy or combined with a weak 
opioid such as hydrocodone and if necessary, 
adjuvant analgesic can be added. In the case of severe 
pain, NSAID can be combined with strong opioid and 
adjuvant analgesic if necessary. 4 
Analgesic or painkiller is a substance that in a 
therapeutic dose, can reduce the pain. Excessive use 
of analgesic might lead to several side effects, such 
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as digestive tract haemorrhage, hepatotoxicity or 
increase the risk factor of kidney failure. 5 
Paracetamol or acetaminophen is a non-opioid 
analgesic that also provide an antipyretic effect. It is 
widely used in case of mild until moderate pain.6,7 
Meanwhile, codeine is a weak opioid analgesic that 
is widely used for treating post-surgery pain, cancer 
pain and other severe pain. Codeine has several side 
effects, such as hypotension, respiratory depression, 
elevated intracranial pressure and gastric 
obstruction.8,9 
Excessive use of analgesic can induce kidney 
damage and increase the risk factor of renal failure. 
There is a various mechanism of kidney injury based 
on the drug, such as by causing chronic interstitial 
inflammation and fibrosis, thickening of the vascular 
wall in the kidney, renal papilla necrosis, and cortex 
necrosis.12  
Serum creatinine is a substance produced by 
catabolism of muscle keratin phosphate. It can be 
used as a marker to assess renal function. Creatinine 
serum level will increase in case of renal toxicity or 
renal injury.13,14  
2. Method 
2.1 Sample and Treatment 
This study uses an experimental research form 
with the Post-Test Only Control Group Design 
approach, which uses 20 male Wistar rats as the 
object of research. Treatment was given for 28 days. 
The experimental animals were divided into four 
groups, namely the control and treatment groups 
(Table 1) where each group consisted of 6 
experimental animals with the following criteria: 
a. Inclusion criteria: (1) male Wistar rats, (2) 2-
3 months old, (3) healthy and active, (4) 
weight 200-250 grams, (5) no anatomical 
abnormalities.  
b. Exclusion criteria: Rats die during adaptation 
and treatment. 
 
 
 
 
 
 
 
 
 
 
 
Table 1.Distribution of control groups and treatment 
groups 
Group Treatment 
K 
Group control that are given standard food 
and drinks 
P1 
Male Wistar rats that are given standard food 
and drinks + Paracetamol dose 32 mg/kg body 
weight four times/day for 28 days  
P2 
Male Wistar rats that are given standard food 
and drinks + codeine dose 1,9 mg/kg body 
weight four times/day for 28 days 
P3 
Male Wistar rats that are given standard food 
and drinks + combination of  paracetamol 
with dose 32 mg/kg body weight and codeine 
1,9 mg/kg body weight four times/day for 28 
days 
 
The dosage of paracetamol and codeine used has 
been converted from human doses to rat doses. The 
dose calculation for paracetamol is 500 mg x 0,018 x 
(50 kg : 70 kg) : 200 x 1000 = 32 mg/kg body weight, 
the dose of codeine 30 mg x 0,018 x (50 kg : 70 kg) : 
200 x 1000 = 1,9 mg/kg body weight, and the 
combination of paracetamol dose 500 mg x 0,018 x 
(50 kg : 70 kg) : 200 x 1000 = 32 mg/kg body weight 
and codeine 30 mg x 0,018 x (50 kg : 70 kg) : 200 x 
1000 = 1,9 mg/kg body weight. 
Before being treated, all Wistar rats were 
acclimatized first for seven days by being caged and 
fed the same standard and drink in ad libitum. After 
that, each group of rats was treated according to the 
above mentioned for 28 days. On the 29th day, blood 
samples were taken through Wistar rat retro-orbital 
blood vessels. Creatinine levels were then measured 
in the Clinical Pathology laboratory. 
 
2.2 Measurement of Creatinine Level 
Blood samples were taken directly from retro-
orbital blood vessels, and then creatinine levels were 
examined by Jaffe examination method without 
deproteinization. The unit used is Mg /dl. 
 
3. Result 
 
3.1 Data analysis 
The data obtained were processed by computer 
programs and analysed by Shapiro-Wilk normality 
test, Levene homogeneity test, and One Way 
ANOVA statistical test. 
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Table 2. Creatinine levels in the control group and 
treatment group 
Groups Mean Standard 
Deviation 
Control 0,3760 0,04615 
Treatment 1 0,3380 0,03033 
Treatment 2 0,3240 0,03057 
Treatment 3 0,3560 0,03847 
 
Table 3. Test for normality and homogeneity 
 
Table 4. One Way ANOVA Test 
 
Groups P 
Control 
0,195* 
Treatment 1 
Treatment 2 
Treatment 3 
*Significant is p<0.05 
  
Based on the result of One Way ANOVA Test, it 
is obtained that the result is not significant. 
 
4. Discussion 
This study compared differences in serum 
creatinine levels in the administration of paracetamol 
and codeine orally. The sample of this study was 20 
Wistar rats based on predetermined inclusion criteria. 
Wistar rats then divided into four groups, namely 5 
Wistar rats as a control group, 5 Wistar rats with oral 
paracetamol administration at a dose of 32 mg/kg 
body weight 4 times per day as a treatment group 1, 
5 Wistar rats with oral codeine dose 1,9 mg/kg body 
weight 4 times per day as treatment group 2 and 5 rats 
with a combination of oral paracetamol dose of 32 
mg/kg body weight and oral codeine dose of 1,9 
mg/kg body weight 4 times per day as a treatment 
group 3. Each group was treated for 28 days. 
The results of this study found out that there is no 
significant difference in creatinine levels between 
treatment group 1, treatment group 2, treatment group 
3 and a control group. 
In treatment group 1, which is given standard 
food and drink and paracetamol dose 32 mg/kg body 
weight did not give a significant difference in 
creatinine serum level. Mechanism of renal injury 
induced by paracetamol is still unclear. One of the 
hypothesis widely accepted is that paracetamol 
metabolite, NAPQI, which is produced by oxidation 
will be reduced by glutathione into mercapturate acid. 
If there is a high concentration of NAPQI, glutathione 
concentration will be reduced drastically. This 
condition will initiate lipid peroxidase which caused 
cell injury and tubular cells apoptosis.37 
Several factors make the result insignificant, 
such as a dosage of the treatment. Based on previous 
research by Suchismita Roy, administration of 
paracetamol dose 550 mg/kg body weight on Wistar 
rats for 14 days will give nephrotoxic effect in the 
form of elevated creatinine serum level and 
degenerative changes on tubular cells in a significant 
level compared to the control groups which only 
given standard food and drink.35 
Another factor is the duration of the treatment. In 
this research, the researcher only gives the treatment 
for 28 days. Based on previous research by Cynthia 
A. Naughton, administration of paracetamol with the 
dosage of more than 1 gram per day for two years will 
increase the risk of chronic interstitial nephropathy.36 
In treatment group 2, which is given standard 
food and drink and codeine dose 1,9 mg/kg body 
weight did not give a significant difference in 
creatinine serum level. Renal injury is induced by 
codeine’s active metabolite, which is morphine.39 
Morphine cause degeneration on renal tubular cells 
by inhibiting glutathione reductase hence free radical 
will be elevated in cell and leads to cell injury.40 
Dosage of codeine administration can be a factor 
that caused the insignificant result. Based on previous 
research, administration of high dose codeine (25 
mg/kg body weight) and extreme dose codeine (50 
mg/kg body weight) for 28 days results in a 
significant increase of creatinine serum level of male 
Wistar rats.38 
In treatment 3 group, which is given combination 
of standard food and oral paracetamol dose of 32 
mg/kg bodyweight and oral codeine dose of 1,9 
mg/kg bodyweight for 28 days also did not give a 
significant difference in creatinine serum level. This 
result can be affected by the dosage of administration. 
Until now, no research measured the effect of a 
combination of paracetamol and codeine on 
creatinine serum, however there is previous research 
conducted that shows 500 mg paracetamol mg 
combined with 30 mg codeine could give effective 
analgesic effects and insignificant side effect.41 
Administration of 650 mg paracetamol and 60 mg 
codeine increase drug’s side effects.42 
Limitations in this study are that the authors 
cannot control several factors, including other disease 
factors, as well as intrinsic factors such as resistance 
and susceptibility of mice. Besides, the lack of 
Groups Shapiro – Wilk Levene Statistic 
Sig. Sig. 
Control 0,568 
 
0.994 
Treatment 1 0,086 
Treatment 2 0,492 
Treatment 3 0,083 
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research time caused the authors to be unable to vary 
the duration of drug administration. 
5. Conclusion 
In this study, it can be concluded that 
administration of a combination of paracetamol with 
a dose of 32 mg/kg body weight and codeine dose of 
1,9 mg/kg body weight four times a day for 28 days 
orally did not cause a significant difference in serum 
creatinine level. 
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